Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

On the numerical solution of the exact factorization equations.

Gossel GH, Lacombe L, Maitra NT.

J Chem Phys. 2019 Apr 21;150(15):154112. doi: 10.1063/1.5090802.

PMID:
31005081
2.

Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series.

Haider M, Ladurner C, Mayr R, Tandogdu Z, Fritsche HM, Fradet V, Comploj E, Pycha A, Lemire F, Lacombe L, Fradet Y, Toren P, Lodde M.

Urol Oncol. 2019 May;37(5):300.e9-300.e15. doi: 10.1016/j.urolonc.2019.01.017. Epub 2019 Mar 12.

PMID:
30871997
3.

Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody.

Émond JP, Labriet A, Desjardins S, Rouleau M, Villeneuve L, Hovington H, Brisson H, Lacombe L, Simonyan D, Caron P, Périgny M, Têtu B, Fallon JK, Klein K, Smith PC, Zanger UM, Guillemette C, Lévesque E.

Drug Metab Dispos. 2019 May;47(5):444-452. doi: 10.1124/dmd.119.086330. Epub 2019 Feb 28.

PMID:
30819787
4.

Psychosocial adjustment to a prostate cancer diagnosis in a cohort of radical prostatectomy patients in Quebec, Canada.

Wissing MD, Chevalier S, O'Flaherty A, McKercher G, Aprikian S, Saad F, Carmel M, Lacombe L, Hamel M, Aprikian A.

Psychooncology. 2019 Apr;28(4):839-846. doi: 10.1002/pon.5031. Epub 2019 Feb 27.

PMID:
30762265
5.

Widespread and Functional RNA Circularization in Localized Prostate Cancer.

Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, Volik S, Lapuk A, Chua MLK, Heisler LE, Foucal A, Fox NS, Fraser M, Bhandari V, Shiah YJ, Guan J, Li J, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Fradet Y, Têtu B, Liu S, Feng F, Wu X, Shao YW, Komor MA, Sahinalp C, Collins C, Hoogstrate Y, de Jong M, Fijneman RJA, Fei T, Jenster G, van der Kwast T, Bristow RG, Boutros PC, He HH.

Cell. 2019 Feb 7;176(4):831-843.e22. doi: 10.1016/j.cell.2019.01.025.

PMID:
30735634
6.

A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer.

Lévesque E, Caron P, Lacombe L, Turcotte V, Simonyan D, Fradet Y, Aprikian A, Saad F, Carmel M, Chevalier S, Guillemette C.

Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):701-706. doi: 10.1158/1055-9965.EPI-18-1002. Epub 2019 Feb 7.

PMID:
30733309
7.

Density-Matrix Coupled Time-Dependent Exchange-Correlation Functional Approximations.

Lacombe L, Maitra NT.

J Chem Theory Comput. 2019 Mar 12;15(3):1672-1678. doi: 10.1021/acs.jctc.8b01159. Epub 2019 Feb 14.

PMID:
30689380
8.

Discordance between testosterone measurement methods in castrated prostate cancer patients.

Rouleau M, Lemire F, Déry M, Thériault B, Dubois G, Fradet Y, Toren P, Guillemette C, Lacombe L, Klotz L, Saad F, Guérette D, Pouliot F.

Endocr Connect. 2019 Jan 1. pii: EC-18-0476. doi: 10.1530/EC-18-0476. [Epub ahead of print]

9.

Exploring non-adiabatic approximations to the exchange-correlation functional of TDDFT.

Fuks JI, Lacombe L, Nielsen SEB, Maitra NT.

Phys Chem Chem Phys. 2018 Nov 7;20(41):26145-26160. doi: 10.1039/c8cp03957g. Epub 2018 Oct 12.

PMID:
30311615
10.

The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.

Ouellet V, Aprikian A, Bergeron A, Brimo F, Bristow RG, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, Karakiewicz P, Klotz L, Lacombe L, Lattouf JB, van der Kwast T, Squire JA, Latour M, Trudel D, Mes-Masson AM, Saad F.

BMC Urol. 2018 Sep 10;18(1):78. doi: 10.1186/s12894-018-0392-x.

11.

The relationship between body-mass index, physical activity, and pathologic and clinical outcomes after radical prostatectomy for prostate cancer.

Wissing M, Chevalier S, McKercher G, Laprise C, Aprikian S, O'Flaherty A, Scarlata E, Saad F, Carmel M, Lacombe L, Brimo F, Latour M, Ekindi-Ndongo N, Têtu B, Aprikian A.

World J Urol. 2019 May;37(5):789-798. doi: 10.1007/s00345-018-2457-6. Epub 2018 Aug 22.

PMID:
30136199
12.

Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer.

Wissing M, Brimo F, Chevalier S, Scarlata E, McKercher G, O'Flaherty A, Aprikian S, Thibodeau V, Saad F, Carmel M, Lacombe L, Têtu B, Ekindi-Ndongo N, Latour M, Trudel D, Aprikian A.

BJU Int. 2019 Apr;123(4):624-631. doi: 10.1111/bju.14512. Epub 2018 Sep 11.

PMID:
30113732
13.

Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer.

Pelletier J, Cyr SJ, Julien AS, Fradet Y, Lacombe L, Toren P.

Urol Oncol. 2018 Aug;36(8):363.e7-363.e11. doi: 10.1016/j.urolonc.2018.05.004. Epub 2018 Jun 5.

PMID:
29880461
14.

Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma.

Locke JA, Hamidizadeh R, Kassouf W, Rendon RA, Bell D, Izawa J, Chin J, Kapoor A, Shayegen B, Lattouf JB, Saad F, Lacombe L, Fradet Y, Fairey AS, Jacobson NE, Drachenberg DE, Cagiannos I, So AI, Black PC.

Can Urol Assoc J. 2018 Aug;12(8):243-251. doi: 10.5489/cuaj.5377. Epub 2018 Apr 12.

15.

A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores.

Leyh-Bannurah SR, Trudel D, Latour M, Zaffuto E, Grosset AA, Tam C, Ouellet V, Graefen M, Budäus L, Aprikian AG, Lacombe L, Fleshner NE, Gleave ME, Mes-Masson AM, Saad F, Karakiewicz PI.

Pathol Oncol Res. 2018 Apr 6. doi: 10.1007/s12253-018-0408-6. [Epub ahead of print]

PMID:
29623528
16.

Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration.

Lavallée E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F.

Eur Urol Focus. 2018 Mar 30. pii: S2405-4569(18)30086-5. doi: 10.1016/j.euf.2018.03.008. [Epub ahead of print]

PMID:
29609897
17.

Exact Time-Dependent Exchange-Correlation Potential in Electron Scattering Processes.

Suzuki Y, Lacombe L, Watanabe K, Maitra NT.

Phys Rev Lett. 2017 Dec 29;119(26):263401. doi: 10.1103/PhysRevLett.119.263401. Epub 2017 Dec 27.

PMID:
29328727
18.

Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review.

Allaire J, Ben-Zvi T, Lamarche B, Robitaille K, Fradet Y, Lacombe L, Fradet V.

Can Urol Assoc J. 2017 Dec;11(12):419-424. doi: 10.5489/cuaj.4471. Epub 2017 Nov 1. Review.

19.

Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study.

Allaire J, Léger C, Ben-Zvi T, Nguilé-Makao M, Fradet Y, Lacombe L, Fradet V.

Nutr Cancer. 2017 Nov-Dec;69(8):1196-1204. doi: 10.1080/01635581.2017.1367941. Epub 2017 Oct 30.

PMID:
29083243
20.

Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors.

Fradet V, Toren P, Nguile-Makao M, Lodde M, Lévesque J, Léger C, Caron A, Bergeron A, Ben-Zvi T, Lacombe L, Pouliot F, Tiguert R, Dujardin T, Fradet Y.

BJU Int. 2018 Mar;121(3):399-404. doi: 10.1111/bju.14041. Epub 2017 Oct 25.

21.

Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy.

Morin F, Beauregard JM, Bergeron M, Nguile Makao M, Lacombe L, Fradet V, Fradet Y, Pouliot F.

Eur Urol Focus. 2017 Dec;3(6):639-642. doi: 10.1016/j.euf.2017.02.007. Epub 2017 Feb 23.

22.

Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative.

Bansal RK, Tanguay S, Finelli A, Rendon R, Moore RB, Breau RH, Lacombe L, Black PC, Kawakami J, Drachenberg D, Pautler S, Saarela O, Liu Z, Jewett MAS, Kapoor A.

Can Urol Assoc J. 2017 Jun;11(6):182-187. doi: 10.5489/cuaj.4264.

23.

A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.

Chua MLK, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V, Mahamud O, Gopalan A, Kweldam CF, van Leenders GJLH, Verhoef EI, Hoogland AM, Livingstone J, Berlin A, Dal Pra A, Meng A, Zhang J, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Fradet Y, Têtu B, Reuter VE, Fleshner N, Fraser M, Boutros PC, van der Kwast TH, Bristow RG.

Eur Urol. 2017 Nov;72(5):665-674. doi: 10.1016/j.eururo.2017.04.034. Epub 2017 May 13.

PMID:
28511883
24.

Erratum to "The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System" [Urol Oncol 34(11) (2016) 486.e1-486.e7].

Mason R, Kapoor A, Liu Z, Saarela O, Tanguay S, Jewett M, Finelli A, Lacombe L, Kawakami J, Moore R, Morash C, Black P, Rendon RA.

Urol Oncol. 2017 Mar;35(3):124. doi: 10.1016/j.urolonc.2017.01.018. No abstract available.

PMID:
28215848
25.

Genomic hallmarks of localized, non-indolent prostate cancer.

Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X, Masella AP, Fox NS, Xie M, Prokopec SD, Berlin A, Lalonde E, Ahmed M, Trudel D, Luo X, Beck TA, Meng A, Zhang J, D'Costa A, Denroche RE, Kong H, Espiritu SM, Chua ML, Wong A, Chong T, Sam M, Johns J, Timms L, Buchner NB, Orain M, Picard V, Hovington H, Murison A, Kron K, Harding NJ, P'ng C, Houlahan KE, Chu KC, Lo B, Nguyen F, Li CH, Sun RX, de Borja R, Cooper CI, Hopkins JF, Govind SK, Fung C, Waggott D, Green J, Haider S, Chan-Seng-Yue MA, Jung E, Wang Z, Bergeron A, Dal Pra A, Lacombe L, Collins CC, Sahinalp C, Lupien M, Fleshner NE, He HH, Fradet Y, Tetu B, van der Kwast T, McPherson JD, Bristow RG, Boutros PC.

Nature. 2017 Jan 19;541(7637):359-364. doi: 10.1038/nature20788. Epub 2017 Jan 9.

PMID:
28068672
26.

Quality indicators in the management of bladder cancer: A modified Delphi study.

Khare SR, Aprikian A, Black P, Blais N, Booth C, Brimo F, Chin J, Chung P, Drachenberg D, Eapen L, Fairey A, Fleshner N, Fradet Y, Gotto G, Izawa J, Jewett M, Kulkarni G, Lacombe L, Moore R, Morash C, North S, Rendon R, Saad F, Shayegan B, Siemens R, So A, Sridhar SS, Traboulsi SL, Kassouf W.

Urol Oncol. 2017 Jun;35(6):328-334. doi: 10.1016/j.urolonc.2016.12.003. Epub 2017 Jan 3.

PMID:
28065393
27.

Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.

Lalonde E, Alkallas R, Chua MLK, Fraser M, Haider S, Meng A, Zheng J, Yao CQ, Picard V, Orain M, Hovington H, Murgic J, Berlin A, Lacombe L, Bergeron A, Fradet Y, Têtu B, Lindberg J, Egevad L, Grönberg H, Ross-Adams H, Lamb AD, Halim S, Dunning MJ, Neal DE, Pintilie M, van der Kwast T, Bristow RG, Boutros PC.

Eur Urol. 2017 Jul;72(1):22-31. doi: 10.1016/j.eururo.2016.10.013. Epub 2016 Nov 1.

PMID:
27815082
28.

A Simple Variable Number of Tandem Repeat-Based Genotyping Strategy for the Detection of Handling Errors and Validation of Sample Identity in Biobanks.

Pellerin C, McKercher G, Aprikian AG, Saad F, Lacombe L, Carmel M, Chevalier S.

Biopreserv Biobank. 2016 Oct;14(5):383-389. Epub 2016 Jun 21.

PMID:
27327090
29.

Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.

Scheid E, Major P, Bergeron A, Finn OJ, Salter RD, Eady R, Yassine-Diab B, Favre D, Peretz Y, Landry C, Hotte S, Mukherjee SD, Dekaban GA, Fink C, Foster PJ, Gaudet J, Gariepy J, Sekaly RP, Lacombe L, Fradet Y, Foley R.

Cancer Immunol Res. 2016 Oct;4(10):881-892. Epub 2016 Sep 7.

30.

Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer.

Forbes CM, Rendon RA, Finelli A, Kapoor A, Moore RB, Breau RH, Lacombe L, Kawakami J, Drachenberg DE, Pautler SE, Jewett MMA, Saarela O, Liu Z, Tanguay S, Black PC.

Urol Oncol. 2016 Nov;34(11):486.e17-486.e23. doi: 10.1016/j.urolonc.2016.05.034. Epub 2016 Jul 14.

PMID:
27423824
31.

The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System.

Mason R, Kapoor A, Liu Z, Saarela O, Tanguay S, Jewett M, Finelli A, Lacombe L, Kawakami J, Moore R, Morash C, Black P, Rendon RA.

Urol Oncol. 2016 Nov;34(11):486.e1-486.e7. doi: 10.1016/j.urolonc.2016.05.025. Epub 2016 Jun 22. Erratum in: Urol Oncol. 2017 Mar;35(3):124.

PMID:
27344410
32.

Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes.

Nayak JG, Patel P, Saarela O, Liu Z, Kapoor A, Finelli A, Tanguay S, Rendon R, Moore R, Black PC, Lacombe L, Breau RH, Kawakami J, Drachenberg DE.

Urology. 2016 Aug;94:154-60. doi: 10.1016/j.urology.2016.03.029. Epub 2016 Mar 31.

PMID:
27041471
33.

Renal cell carcinoma with thrombus extending to the hepatic veins or right atrium: operative strategies based on 41 consecutive patients.

Gagné-Loranger M, Lacombe L, Pouliot F, Fradet V, Dagenais F.

Eur J Cardiothorac Surg. 2016 Aug;50(2):317-21. doi: 10.1093/ejcts/ezw023. Epub 2016 Mar 25.

PMID:
27016196
34.

CUA guidelines on the management of non-muscle invasive bladder cancer.

Kassouf W, Traboulsi SL, Kulkarni GS, Breau RH, Zlotta A, Fairey A, So A, Lacombe L, Rendon R, Aprikian AG, Siemens DR, Izawa JI, Black P.

Can Urol Assoc J. 2015 Sep-Oct;9(9-10):E690-704. doi: 10.5489/cuaj.3320. Epub 2015 Oct 13. No abstract available.

35.

Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction.

Lacombe L, Fradet V, Lévesque É, Pouliot F, Larue H, Bergeron A, Hovington H, Caron A, Nguile-Makao M, Harvey M, Fradet Y, Guillemette C.

Cancer Prev Res (Phila). 2016 Feb;9(2):189-95. doi: 10.1158/1940-6207.CAPR-15-0069. Epub 2015 Dec 8.

36.

Canadian guidelines for the management of small renal masses (SRM).

Jewett MA, Rendon R, Lacombe L, Karakiewicz PI, Tanguay S, Kassouf W, Leveridge M, Cagiannos I, Kapoor A, Pautler S, Drachtenberg D, Moore R, Gleave M, Evans A, Haider M, Finelli A.

Can Urol Assoc J. 2015 May-Jun;9(5-6):160-3. doi: 10.5489/cuaj.2969. No abstract available.

37.

The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression.

Belledant A, Hovington H, Garcia L, Caron P, Brisson H, Villeneuve L, Simonyan D, Têtu B, Fradet Y, Lacombe L, Guillemette C, Lévesque E.

Eur Urol. 2016 Apr;69(4):601-609. doi: 10.1016/j.eururo.2015.06.054. Epub 2015 Jul 26.

PMID:
26215610
38.

Surgical management of stage T1 renal tumours at Canadian academic centres.

Lavallée LT, Tanguay S, Jewett MA, Wood L, Kapoor A, Rendon RA, Moore RB, Lacombe L, Kawakami J, Pautler SE, Drachenberg DE, Black PC, Lattouf JB, Morash C, Cagiannos I, Liu Z, Breau RH.

Can Urol Assoc J. 2015 Mar-Apr;9(3-4):99-106. doi: 10.5489/cuaj.2598. Erratum in: Can Urol Assoc J. 2016 Aug;10 (7-8):E281.

39.

Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy.

Desmeules P, Hovington H, Nguilé-Makao M, Léger C, Caron A, Lacombe L, Fradet Y, Têtu B, Fradet V.

Diagn Pathol. 2015 Jun 13;10:67. doi: 10.1186/s13000-015-0294-0.

40.

FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy.

Beauregard JM, Blouin AC, Fradet V, Caron A, Fradet Y, Lemay C, Lacombe L, Dujardin T, Tiguert R, Rimac G, Bouchard F, Pouliot F.

Cancer Imaging. 2015 Mar 3;15:2. doi: 10.1186/s40644-015-0038-0.

41.

CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy.

Escamilla J, Schokrpur S, Liu C, Priceman SJ, Moughon D, Jiang Z, Pouliot F, Magyar C, Sung JL, Xu J, Deng G, West BL, Bollag G, Fradet Y, Lacombe L, Jung ME, Huang J, Wu L.

Cancer Res. 2015 Mar 15;75(6):950-62. doi: 10.1158/0008-5472.CAN-14-0992. Epub 2015 Mar 3.

42.

Low level of the X-linked ribosomal protein S4 in human urothelial carcinomas is associated with a poor prognosis.

Paquet ÉR, Hovington H, Brisson H, Lacombe C, Larue H, Têtu B, Lacombe L, Fradet Y, Lebel M.

Biomark Med. 2015;9(3):187-97. doi: 10.2217/bmm.14.115.

PMID:
25731206
43.

The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence.

Kapoor A, Dason S, Allard CB, Shayegan B, Lacombe L, Rendon R, Jacobsen NE, Fairey A, Izawa J, Black P, Tanguay S, Chin J, So A, Lattouf JB, Bell D, Saad F, Drachenberg D, Cagiannos I, Fradet Y, Alamri A, Kassouf W.

Can Urol Assoc J. 2014 Nov;8(11-12):E845-52. doi: 10.5489/cuaj.1985.

44.

The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy.

Laverdière I, Flageole C, Audet-Walsh É, Caron P, Fradet Y, Lacombe L, Lévesque É, Guillemette C.

Endocr Relat Cancer. 2015 Feb;22(1):77-85. doi: 10.1530/ERC-14-0423. Epub 2014 Dec 1.

PMID:
25452636
45.

Cystatin C for early detection of acute kidney injury after laparoscopic partial nephrectomy.

Alesawi A, Nadeau G, Bergeron A, Dujardin T, Lacombe L, Caumartin Y.

Urol Ann. 2014 Oct;6(4):298-304. doi: 10.4103/0974-7796.140988.

46.

Conditional survival after radical nephroureterectomy for upper tract carcinoma.

Ploussard G, Xylinas E, Lotan Y, Novara G, Margulis V, Rouprêt M, Matsumoto K, Karakiewicz PI, Montorsi F, Remzi M, Seitz C, Scherr DS, Kapoor A, Fairey AS, Rendon R, Izawa J, Black PC, Lacombe L, Shariat SF, Kassouf W.

Eur Urol. 2015 Apr;67(4):803-12. doi: 10.1016/j.eururo.2014.08.003. Epub 2014 Aug 19.

PMID:
25145551
47.

Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration.

Fradet V, Mauermann J, Kassouf W, Rendon R, Jacobsen N, Fairey A, Izawa J, Kapoor A, Black P, Tanguay S, Chin J, So A, Lattouf JB, Bell D, Saad F, Sheyegan B, Drachenberg D, Cagiannos I, Lacombe L.

Urol Oncol. 2014 Aug;32(6):839-45. doi: 10.1016/j.urolonc.2014.04.006. Epub 2014 May 22.

PMID:
24856978
48.

Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer.

Huang SP, Lévesque E, Guillemette C, Yu CC, Huang CY, Lin VC, Chung IC, Chen LC, Laverdière I, Lacombe L, Fradet Y, Chang TY, Lee HZ, Juang SH, Bao BY.

Int J Cancer. 2014 Dec 1;135(11):2661-7. doi: 10.1002/ijc.28904. Epub 2014 Apr 22.

49.

Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway.

Lévesque E, Laverdière I, Audet-Walsh E, Caron P, Rouleau M, Fradet Y, Lacombe L, Guillemette C.

Clin Cancer Res. 2014 Jun 1;20(11):2971-83. doi: 10.1158/1078-0432.CCR-13-2567. Epub 2014 Mar 28.

50.

Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration.

Bachir BG, Aprikian AG, Izawa JI, Chin JL, Fradet Y, Fairey A, Estey E, Jacobsen N, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Kapoor A, Matsumoto E, Saad F, Bell D, Black PC, So AI, Drachenberg D, Kassouf W.

Urol Oncol. 2014 May;32(4):441-8. doi: 10.1016/j.urolonc.2013.10.016. Epub 2014 Jan 10.

PMID:
24412632

Supplemental Content

Loading ...
Support Center